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for other M. avium complex members, lower MIC50 (฀0.25 mg/L), MIC90 (0.5 mg/L) and ECOFF (1
mg/L) values were found for M. kansasii Susceptibility to clarithromycin, ethambutol, rifampin, rifabutin,
amikacin, moxifloxacin and linezolid was in general similar for M. chimaera and other members of the
M. avium complex but increased for M. kansasii The herein determined MIC distributions, MIC90 and
ECOFF values of clofazimine for M. chimaera and other NTM provide the basis for the definition of
clinical breakpoints. Further studies are needed to establish correlation of in vitro susceptibility and
clinical outcome.
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ABSTRACT 27 
Recent outbreaks of cardiac surgery-associated Mycobacterium chimaera infections 28 
have highlighted the importance of species differentiation within the Mycobacterium 29 
avium complex and pointed to a lack of antibiotic susceptibility data for M. chimaera. 30 
Using the MGIT 960/EpiCenter TB eXiST platform, we have determined antibiotic 31 
susceptibility patterns of 48 clinical M. chimaera isolates and 139 other non-32 
tuberculous mycobacteria including 119 members of the M. avium complex and 20 33 
Mycobacterium kansasii towards clofazimine and other drugs used to treat infections 34 
with slowly growing nontuberculous mycobacteria (NTM). MIC50, MIC90 and tentative 35 
epidemiological cutoff (ECOFF) values for clofazimine were 0.5 mg/L, 1 mg/L and 36 
2 mg/L for M. chimaera. Comparable values were observed for other M. avium 37 
complex members, lower MIC50 (≤0.25 mg/L), MIC90 (0.5 mg/L) and ECOFF (1 mg/L) 38 
values were found for M. kansasii. Susceptibility to clarithromycin, ethambutol, 39 
rifampin, rifabutin, amikacin, moxifloxacin and linezolid was in general similar for 40 
M. chimaera and other members of the M. avium complex but increased for 41 
M. kansasii. The herein determined MIC distributions, MIC90 and ECOFF values of 42 
clofazimine for M. chimaera and other NTM provide the basis for the definition of 43 
clinical breakpoints. Further studies are needed to establish correlation of in vitro 44 
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INTRODUCTION 47 
 48 
Mycobacterium chimaera is a slowly growing non-tuberculous mycobacterium (NTM), 49 
which was established in 2004 as a new species within the Mycobacterium avium 50 
complex (1). In the past, the number of infections with M. chimaera was 51 
underestimated as commercial mycobacterial identification systems such as line 52 
probe assays failed to identify M. chimaera to species level and classified 53 
M. chimaera as M. avium complex, M. avium or Mycobacterium intracellulare (1, 2). 54 
M. chimaera is differentiated from other members of the M. avium complex by a 55 
unique 16S rRNA gene sequence and internal transcribed spacer (ITS) region (1). 56 
Recently, a global outbreak of cardiac surgery-associated M. chimaera infections 57 
highlighted the importance of species identification within the M. avium complex (3, 58 
4). The outbreak was linked to contaminated water reservoirs of heater-cooler 59 
devices that spread M. chimaera by aerosols during open chest surgery (5, 6). 60 
Severe, disseminated M. chimaera infections with a high case fatality rate were 61 
observed (7).  62 
 63 
Due to the limited ability of commercial identification methods to adequately identify 64 
M. chimaera, few studies have reported drug susceptibility data on M. chimaera. 65 
Recent studies analyzed antimicrobial susceptibility of M. chimaera using a 66 
commercial microdilution system, the SLOWMYCO SensititreTM panel from Trek 67 
Diagnostic Systems, and reported  similar susceptibility patterns for M. chimaera as 68 
for other members of the M. avium complex (8-11). Recommended treatment options 69 
for disseminated M. chimaera infections include combination therapy with 70 
macrolides, rifamycins, ethambutol, amikacin and clofazimine (7). Clofazimine is not 71 


















































  Page 4 of 26 
clofazimine MIC data for M. chimaera are scarce. We have previously established 73 
automated quantitative drug susceptibility testing for slowly growing NTM using the 74 
MGIT 960/EpiCenter TB eXiST platform (12, 13). We here report on minimal 75 
inhibitory concentration (MIC) distributions of clofazimine and other drugs used to 76 
treat NTM infections for 48 clinical M. chimaera isolates and 139 other non-77 
tuberculous mycobacteria, including 119 members of the M. avium complex and 78 
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MATERIALS AND METHODS 81 
 82 
Mycobacterial strains and culture conditions. Drug susceptibility of 48 non-83 
duplicate clinical isolates of M. chimaera and 139 additional slowly growing non-84 
tuberculous mycobacteria from respiratory and non-respiratory origin including the 85 
M. avium complex isolates M. avium (n=80), M. intracellulare (n=31), M. yongonense 86 
(n=3), M. timonense (n=2), M. bouchedurhonense (n=1), M. colombiense (n=1) and 87 
M. vulneris (n=1), and M. kansasii (n=20) that were submitted to or isolated at our 88 
mycobacteriological laboratory from 2014 to 2018 was measured in this study (Table 89 
1). In addition, the type strains M. avium ATCC 19421 and M. chimaera DSM 44623 90 
were analyzed. The isolates were identified by partial 16S rRNA gene sequence 91 
analysis as described previously (14). M. kansasii was differentiated by sequence 92 
analysis of the hsp65 gene (15). Mycobacteria were grown in Mycobacterium Growth 93 
Indicator Tube medium supplemented with oleic albumin dextrose catalase (OADC) 94 
(Beckton Dickinson, Sparks, MD) at 37°C. 95 
 96 
Drug susceptibility testing. Drug susceptibility distributions of NTM were 97 
determined by automated, quantitative drug susceptibility testing (DST) using the 98 
MGIT 960 system and the Epicenter TB eXIST system (Beckton Dickinson) as 99 
described before (12, 13). The antibiotics amikacin (1, 4, 20 mg/L), clarithromycin (4, 100 
16, 32, 64 mg/L), clofazimine (0.25, 0.5, 1, 2, 4 mg/L), ethambutol (5, 12.5, 50 mg/L), 101 
linezolid (1, 4, 16 mg/L), moxiflocaxin (0.5, 2.5, 10 mg/L), rifabutin (0.1, 0.4, 2 mg/L) 102 
and rifampin (1, 4, 20 mg/L) were analyzed. Clofazimine was purchased from Sigma 103 
(Sigma-Aldrich, Buchs, Switzerland) and dissolved in 100% dimethyl sulfoxide 104 
(DMSO). The terms susceptible (S), intermediate (I), and resistant (R) are used in 105 
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concentration and do neither represent clinical breakpoints nor predict clinical 107 
outcome. Intermediate growth inhibition represents significant (>99%) but not 108 
complete inhibition and was categorized susceptible (S) for calculating minimal 109 
inhibitory concentration (MIC) values and depict distributions at the population level. 110 
 111 
Clarithromycin and amikacin resistance analysis. Phenotypic clarithromycin and 112 
amikacin resistance was confirmed by sequence analysis of the 23S rRNA gene and 113 
16S rRNA gene, respectively, as described elsewhere (16, 17). Mutations at 114 
nucleotide position A2058 and A2059 (E. coli equivalent) of the 23S rRNA gene were 115 
considered as resistance markers for macrolides, and mutations at nucleotide 116 
position A1408 and C1409 (E. coli equivalent) of the 16S rRNA gene were 117 
considered as amikacin resistance markers. 118 
 119 
Determination of ECOFF, MIC50 and MIC90. MIC distributions were generated from 120 
the quantitative DST results. Epidemiological cutoffs (ECOFFs) were determined by 121 
visual inspection of the MIC distributions (18). MIC50 and MIC90 was defined as drug 122 
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RESULTS 125 
M. chimaera clofazimine MIC distribution. Minimal inhibitory concentrations (MIC) 126 
of clofazimine were determined for 48 clinical, non-duplicate M. chimaera isolates 127 
using the MGIT 960/EpiCenter TB eXiST system. A clofazimine concentration range 128 
of 0.25 mg/L to 4 mg/L was tested in two-fold serial dilutions. Thirty-four out of 48 129 
(71%) M. chimaera isolates were of respiratory origin, and 13 out of 48 (27%) 130 
isolates were of non-respiratory origin (Table 1). For one isolate the source was 131 
unknown. Clofazimine MIC values for M. chimaera ranged from ≤0.25 mg/L to 2 mg/L 132 
(Figure 1A, Table 2). MIC50 and MIC90 values of 0.5 mg/L and 1 mg/L were 133 
determined. A tentative ECOFF was set at 2 mg/L by visual inspection of the MIC 134 
distribution (Figure 1). The clofazimine MIC distribution of M. chimaera was 135 
compared to MIC distributions of 119 M. avium complex isolates including M. avium 136 
(n=80), M. intracellulare (n=31), M. yongonense (n=3), M. timonense (n=2), 137 
M. bouchedurhonense (n=1), M. colombiense (n=1) and M. vulneris (n=1) (Figure 1B-138 
E, Table 2). The MIC range, MIC50, MIC90 and tentative ECOFF of M. chimaera and 139 
other M. avium complex isolates were comparable. The clofazimine MIC distribution 140 
of M. kansasii, a slowly growing non-tuberculous mycobacterium not related to the 141 
M. avium complex, showed lower MIC50 (≤0.25 mg/L), MIC90 (0.5 mg/L) and tentative 142 
ECOFF values (1 mg/L) compared to M. chimaera and other M. avium complex 143 
species (Figure 1F). 144 
 145 
Susceptibility distributions of additional drugs used for the treatment of 146 
M. chimaera infections. Susceptibility patterns of additional drugs used for the 147 
treatment of M. chimaera infections such as clarithromycin, ethambutol, rifampin, 148 
rifabutin, amikacin, moxifloxacin and linezolid are shown in figure 2 and table 2 for 149 


















































  Page 8 of 26 
drugs was in general comparable for M. chimaera and other members of the 151 
M. avium complex. Lower MIC values were observed for M. kansasii towards 152 
amikacin, linezolid, moxifloxacin, rifampin, and rifabutin when compared to 153 
M. chimaera and M. avium complex. 154 
 155 
Macrolide and amikacin resistance. For two M. avium isolates and one isolate of 156 
each M. chimaera and M. intracellulare MIC values of ≥32 mg/L were observed for 157 
clarithromycin which indicates macrolide resistance according to CLSI guidelines 158 
(19). Sequence analysis of the 23S rRNA gene of both M. avium isolates and 159 
M. intracellulare revealed mutations at nucleotide position A2059G (E. coli 160 
numbering) thereby providing a genotypic confirmation of the high level macrolide 161 
resistance phenotype. However, for the M. chimaera isolate no mutation could be 162 
detected at nucleotide positions A2058/A2059. Repeated clarithromycin testing 163 
confirmed the decreased in vitro macrolide susceptibility of this isolate that was 164 
observed after prolonged macrolide treatment. Two M. avium and two 165 
M. intracellulare isolates exhibited MIC values of ≥20 mg/L for amikacin. One 166 
M. intracellulare isolate exhibited an A1408G mutation in the 16S rRNA gene (E. coli 167 
numbering) which is known to confer high-level aminoglycoside resistance (20, 21). 168 
In contrast, the second M. intracellulare isolate and the two M. avium isolates carried 169 
a wild type 16S rRNA allele. Therefore, the molecular mechanisms underlying 170 
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DISCUSSION 173 
 174 
Treatment of M. chimaera and M. avium complex infections is complicated and 175 
requires multi-drug regimens. Treatment options are limited especially for macrolide-176 
resistant isolates (7). Clofazimine, a drug traditionally used in leprosy therapy and 177 
recently recommended by the World Health Organization (WHO) for the treatment of 178 
multi-drug resistant tuberculosis (MDR-TB), is also increasingly used to treat severe 179 
M. avium complex infections (22, 23). Elevated MICs for clofazimine have been 180 
reported for M. avium and M. intracellulare and suggest the occurrence of resistant 181 
isolates (24). Whereas for Mycobacterium tuberculosis complex the WHO has 182 
released guidelines on clofazimine susceptibility testing and defined clinical 183 
breakpoints, i.e. critical concentrations, to separate resistant from susceptible 184 
isolates, such guidelines are lacking for NTM (25). Determination of MIC distributions 185 
and ECOFFs is a prerequisite for the assignment of clinical breakpoints. 186 
 187 
Clofazimine MIC distribution data have to our knowledge not yet been reported for 188 
M. chimaera. Pang et al. reported a MIC of 0.5 mg/L for clofazimine for the type strain 189 
M. chimaera DSM 44623 (26). We determined the MIC50, MIC90 and ECOFF at 0.5 190 
mg/L, 1 mg/L and 2 mg/L, respectively, based on the MIC distribution of 48 clinical 191 
isolates of M. chimaera using the MGIT 960/EpiCenter TB eXiST platform and 192 
showed that these values are comparable to clofazimine MIC50, MIC90 and ECOFF of 193 
other members of the M. avium complex including M. avium sensu stricto and 194 
M. intracellulare. Our data are in agreement with different reports of clofazimine 195 
susceptibility data for M. avium complex (24, 27-29). A MIC50 of 1 mg/L for M. avium 196 
complex was found by van Ingen et al. (29), and MIC90 values of 4 mg/L and 1 mg/L 197 
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Luo et al. determined a clofazimine ECOFF of 2 mg/L for M. avium and 199 
M. intracellulare (24). The clofazimine MIC distribution of M. kansasii was shifted 200 
towards lower MICs as compared to M. avium complex in our study. This is in line 201 
with the findings that M. kansasii is in general more susceptible to  NTM drugs than 202 
M. avium complex and reports of a clofazimine ECOFF of 0.5 mg/L for M. kansasii by 203 
Luo et al (24). 204 
 205 
Clofazimine resistance in NTM has been associated with mutations in TetR family 206 
regulators of adjacent MmpS5-MmpL5 efflux pumps; mmpT5 in M. intracellulare (30) 207 
and MAB_2299c in M. abscessus (31). The NTM isolates characterized in this study 208 
were therapy naïve regarding clofazimine, and no elevated MIC was observed. 209 
Exploratory investigations in ten randomly selected M. chimaera isolates did not 210 
reveal genetic diversity within the putative homologs RS13290 (mmpt5; 100% amino 211 
acid (aa) sequence identity) and RS24730 (MAB_2299c; 70% aa sequence identity) 212 
of M. chimaera DSM 44623T (CP015278.1) (data not shown). In M. tuberculosis, 213 
mutations in the Rv0678 (mmpR5) locus are associated with clofazimine and 214 
bedaquiline resistance (32, 33). The closest homologs of Rv0678 were RS18640 215 
(35% aa identity), RS15530 (35% aa identity) and RS06670 (24% aa identity) of 216 
M. chimaera DSM 44623T (data not shown). These findings confirm reports of others 217 
that there is no ortholog of Rv0678 (MmpR5) in M. avium complex (30). Furthermore, 218 
unlike RS13290 and RS24730, the latter three genes are not located in the proximity 219 
of mmpL genes.  220 
 221 
The MGIT 960/EpiCenter TB eXiST platform (Beckton Dickinson) is recommended 222 
by the WHO for drug susceptibility testing of M. tuberculosis, including the testing of 223 
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(25). We have previously adapted MGIT 960 testing for automated quantitative drug 225 
susceptibility testing of slowly growing NTM and expanded this method for the testing 226 
of clofazimine within this study (12, 13). Commercial microdilution systems that lack 227 
clofazimine testing, e.g. the SLOWMYCO SensititreTM panel from Trek Diagnostic 228 
Systems, are broadly used for drug susceptibility testing of slowly growing NTM (8-229 
11). MGIT 960 testing of clofazimine, a method established in many laboratories 230 
worldwide for M. tuberculosis complex, could complement commercial microdilution 231 
testing for slowly growing NTM in these laboratories. Our data support the addition of 232 
clofazimine to future commercial microdilution panels for NTM.  233 
 234 
MIC90 values of M. chimaera for drugs other than clofazimine such as amikacin, 235 
clarithromycin, ethambutol, moxifloxacin, linezolid, rifampin and rifampicin are in 236 
agreement with the findings of previous studies for M. chimaera and comparable to 237 
values reported for M. avium complex (1, 8-11, 27).  238 
 239 
In conclusion, we provide MIC distribution, MIC90 and ECOFF of clofazimine for 240 
M. chimaera and demonstrate comparable values for other members of the M. avium 241 
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FIGURES 400 
 401 
FIGURE 1 402 
 403 
Figure 1. MIC distributions of clofazimine for (A) M. chimaera (n=48), (B) M. avium 404 
(n=80), (C) M. intracellulare (n=31), (D) other MAC (n=8), (E) M. avium complex 405 
overall (n=167), and (F) M. kansasii (n=20). Tentative ECOFF (arrow), MIC50 (solid 406 
line) and MIC90 (dashed line) are indicated. The clofazimine MIC value of the type 407 
strains M. avium ATCC 19421 and M. chimaera DSM 44623 is indicated (*). 408 


















































  Page 20 of 26 
FIGURE 2 410 
411 
 412 
Figure 2. Susceptibility distributions for different drugs and NTM species based on 413 
quantitative drug susceptibility testing data using MGIT TB eXiST. Approximated 414 
MIC90 values are indicated (dashed line). MIC values of the type strains M. avium 415 
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TABLES 418 
Table 1. Number and origin of NTM isolates included in this study. 419 
Species 
No. (%) of 
respiratory 
isolates 
No. (%) of 
non-respiratory 
isolates 




M. avium (MAC) 55 (69) 8 (10) 17 (21) 80 
M. intracellulare (MAC) 30 (97) 0 (0) 1 (3) 31 
M. chimaera (MAC) 34 (71) 13 (27) 1 (2) 48 
other MAC 6 (75) 1 (12.5) 1 (12.5) 8 
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Table 2. Assignment of NTM isolates to susceptibility categories in the MGIT 960 422 
system. 423 





  S I R  
Clarithromycin      
M. avium 4 67 11 2 80 
 16 78 0 2  
 32 78 0 2  
 64 78 0 2  
M. chimaera 4 47 0 1 48 
 16 47 0 1  
 32 47 1 0  
 64 48 0 0  
M. intracellulare 4 29 1 1 31 
 16 30 0 1  
 32 30 0 1  
 64 31 0 0  
other MAC 4 8 0 0 8 
 16 8 0 0  
 32 8 0 0  
 64 8 0 0  
M. kansasii 4 20 0 0 20 
 16 20 0 0  
 32 20 0 0  
 64 20 0 0  
Rifampicin      
M. avium 1 2 16 62 80 
 4 25 32 23  
 20 60 18 2  
M. chimaera 1 9 14 25 48 
 4 28 19 1  
 20 48 0 0  
M. intracellulare 1 1 2 28 31 
 4 3 26 2  
 20 30 1 0  
other MAC 1 4 1 3 8 
 4 5 3 0  
 20 8 0 0  
M. kansasii 1 19 0 1 20 
 4 20 0 0  
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Table 2. continued. 426 





  S I R  
Rifabutin      
M. avium 0.1 11 15 54 80 
 0.4 39 34 7  
 2 78 0 2  
M. chimaera 0.1 9 7 32 48 
 0.4 36 10 2  
 2 47 1 0  
M. intracellulare 0.1 0 1 30 31 
 0.4 10 19 2  
 2 31 0 0  
other MAC 0.1 3 2 3 8 
 0.4 5 3 0  
 2 8 0 0  
M. kansasii 0.1 20 0 0 20 
 0.4 20 0 0  
 2 20 0 0  
Ethambutol      
M. avium 5 46 19 15 80 
 12.5 71 4 5  
 50 78 0 2  
M. chimaera 5 19 4 25 48 
 12.5 47 1 0  
 50 48 0 0  
M. intracellulare 5 27 2 2 31 
 12.5 30 0 1  
 50 31 0 0  
other MAC 5 7 1 0 8 
 12.5 8 0 0  
 50 8 0 0  
M. kansasii 5 19 0 1 20 
 12.5 20 0 0  
 50 20 0 0  
 427 
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Table 2. continued. 429 





  S I R  
Amikacin      
M. avium 1 0 0 80 80 
 4 5 27 48  
 20 72 6 2  
M. chimaera 1 0 1 47 48 
 4 18 14 16  
 20 48 0 0  
M. intracellulare 1 1 0 30 31 
 4 3 11 17  
 20 28 1 2  
other MAC 1 3 0 5 8 
 4 4 2 2  
 20 8 0 0  
M. kansasii 1 3 0 17 20 
 4 20 0 0  
 20 20 0 0  
Moxifloxacin      
M. avium 0.5 29 26 25 80 
 2.5 75 3 2  
 10 79 1 0  
M. chimaera 0.5 11 24 13 48 
 2.5 48 0 0  
 10 48 0 0  
M. intracellulare 0.5 3 8 20 31 
 2.5 30 1 0  
 10 31 0 0  
other MAC 0.5 3 1 4 8 
 2.5 7 0 1  
 10 8 0 0  
M. kansasii 0.5 20 0 0 20 
 2.5 20 0 0  
 10 20 0 0  
 430 
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Table 2. continued. 432 





  S I R  
Linezolid      
      
M. avium 1 1 1 78 80 
 4 8 8 64  
 16 27 34 19  
M. chimaera 1 0 2 46 48 
 4 3 13 32  
 16 40 8 0  
M. intracellulare 1 0 1 30 31 
 4 2 5 24  
 16 12 14 5  
other MAC 1 0 0 8 8 
 4 1 3 4  
 16 5 2 1  
M. kansasii 1 15 4 1 20 
 4 20 0 0  
 16 20 0 0  
Clofazimine      
M. avium 0.25 1 4 75 80 
 0.5 9 26 45  
 1 44 28 8  
 2 80 0 0  
 4 80 0 0  
M. chimaera 0.25 3 0 45 48 
 0.5 24 5 19  
 1 39 8 1  
 2 48 0 0  
 4 48 0 0  
M. intracellulare 0.25 0 2 29 31 
 0.5 2 12 17  
 1 17 12 2  
 2 30 1 0  
 4 31 0 0  
other MAC 0.25 0 0 8 8 
 0.5 1 1 6  
 1 4 2 2  
 2 8 0 0  
 4 8 0 0  
M. kansasii 0.25 9 3 8 20 
 0.5 18 1 1  
 1 20 0 0  
 2 20 0 0  
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1 The categories susceptible (S), intermediate (I), and resistant (R) are used in this 433 
study to describe presence or absence of in vitro growth at a defined drug 434 
concentration and do neither represent clinical breakpoints nor predict clinical 435 
outcome. Intermediate growth inhibition represents significant (>99%) but not 436 
complete inhibition and was categorized susceptible (S) for calculating minimal 437 
inhibitory concentration (MIC) values and depicting distributions at the population 438 
level. 439 
 440 
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